Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Acta Psychiatrica Scandinavica. Supplementum|January 1, 1990
Safety evaluation in both short- and long-term treatment of schizophrenia with remoxiprideD Morrison, A Englund, V Lawrie, et al.
Journal of Medicinal Chemistry|December 24, 1993
Derivatives of 2-(dipropylamino)tetralin: effect of the C8-substituent on the interaction with 5-HT1A receptorsY Liu, H Yu, B E Svensson, et al.
The Journal of Pharmacy and Pharmacology|February 1, 1997
Pharmacodynamic and pharmacokinetic studies in rats of S-8-(2-Furyl)- and R-8-phenyl-2-(di-n-propylamino) tetralin, two novel 5-HT1A receptor agonists in-vitro with different properties in-vivoH Yu, Y Liu, H B Li, et al.
Nordic Journal of Psychiatry|February 28, 2002
Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)E Lindström, T Lewander, U Malm, et al.
Pharmacology & Toxicology|October 1, 1988
Prenatal methylazoxymethanol treatment potentiates d-amphetamine- and methylphenidate-induced motor activity in male and female ratsT Archer, A Fredriksson, E Sundström, et al.
Nordic Journal of Psychiatry|February 28, 2002
Assessment of patient satisfaction with psychiatric care. Development and clinical evaluation of a brief consumer satisfaction rating scale (UKU-ConSat)U G Ahlfors, T Lewander, E Lindström, et al.
British Journal of Pharmacology|July 1, 1985
Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgylineT Archer, C J Fowler, A Fredriksson, et al.
Drug Design and Discovery|January 1, 1993
Neuromedicinal chemistry of 5-HT1A-receptor agonists and antagonistsU Hacksell, Y Liu, H Yu, et al.
Psychopharmacology|January 1, 1986
Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the ratT Archer, A Fredriksson, G Jonsson, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1991
Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effectsL Björk, L J Cornfield, D L Nelson, et al.
Pageof 5